SWISS BRIDGE
News
Newsletter: SWISS BRIDGE AWARD 2019
New cellular immunotherapies cannot be compared with classical drugs. Drugs are clearly defined chemical substances, but the new treatments are alive; using cancer patients´ immune systems from their own bodies to fight cancer at the cellular level. Patients´ cells are genetically modified and multiplied in a laboratory – then transferred back into their bodies, where the cells can act with increased strength against degenerated tumour cells, thanks to genetic upgrading.
SWISS BRIDGE AWARD 2019 (DE)
Ein Forschungsteam aus Deutschland und eines aus der Schweiz teilen sich den diesjährigen Swiss Bridge Award. Mit dem Preisgeld von je 250 000 Franken verfolgen die Wissenschaftlerinnen und Wissenschaftler Ansätze, die eine Verringerung der Nebenwirkungen und eine Ausweitung der Anwendungen von zellulären Immuntherapien zum Ziel haben.
SWISS BRIDGE AWARD 2019 (EN)
A research team from Germany and one from Switzerland share this year’s Swiss Bridge Award. Presented with prize money of CHF 250,000 each, the scientists are pursuing approaches that aim at alleviating side effects and expanding the use of cellular immunotherapies.
Contact
Donor details
Donor‘s account
- Credit Suisse | 8070 Zurich
- IBAN:
CH52 0483 5095 7385 1100 0 - PC:
60-559822-6
